L-carnitine + atorvastatin

L-carnitine + atorvastatin is a combination of two agents used primarily for cardiovascular risk reduction and lipid management. Atorvastatin is a statin, or HMG-CoA reductase inhibitor, that lowers cholesterol by inhibiting the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase in the liver, thereby reducing cholesterol synthesis and lowering LDL cholesterol levels[1][3][8]. L-carnitine is a naturally occurring compound involved in fatty acid metabolism; it facilitates the transport of long-chain fatty acids into mitochondria for energy production[2][5]. The combination has been studied particularly in patients with chronic kidney disease (CKD) to improve lipid profiles and hemoglobin levels more effectively than atorvastatin alone, with evidence suggesting improved triglyceride, total cholesterol, LDL reduction, increased HDL and hemoglobin without significant additional side effects[4]. Atorvastatin is developed as a pharmaceutical drug; L-carnitine is available both as a supplement and as an adjunct therapy. This combination has been investigated mainly for its potential to enhance lipid-lowering effects and reduce statin-associated muscle toxicity. L-carnitine may partially protect against statin-induced myopathy but does not eliminate this risk entirely. Atorvastatin is widely approved for hypercholesterolemia and cardiovascular prevention; L-carnitine's use as an adjunct remains investigational or supplemental depending on jurisdiction.

Other names

L-carnitine + atorvastatinL-Carnitina + Atorvastatina